Alpha Lipoic Acid Reduces Symptoms and Inflammation Biomarkers in Patients with Chronic Hemorrhoidal Illness
Abstract
Abstract.Background: Oral dietary supplementation is becoming increasingly popular as an addition to classical approaches for the prevention and treatment of hemorrhoidal disease. Aim: To examine the effect of orally administrated alpha lipoic acid (ALA), known for its antioxidant and anti-inflammatory properties, in the treatment of patients with permanent symptoms of hemorrhoidal disease. Methods: Patients with second- and third-degree hemorrhoids (n = 100) were enrolled into a randomized, open label, single-center trial. The study group (n = 50) was treated with 200 mg of orally administered ALA once a day during the 12-week period, the control group (n = 50) did not receive any treatment. Results: There were no significant differences in demographics, diagnosis, or exposure to major risk factors between the study and placebo group at baseline. ALA significantly improved subjective efficacy variables, such as pain and discomfort (p < 0.01) as well as objective signs of the disease, such as bleeding (p < 0.01), in comparison to the control group. Furthermore, the 3-month treatment significantly reduced the number of patients with positive C-reactive protein (CRP) value (serum CRP > 5 mg/L) from 18% before to only 2% after the treatment (χ2 = 4.65; p < 0.01). Average leukocyte count has also been significantly reduced in the treatment group (p < 0.01) from 7.29 × 109/L before to 6.18 × 109/L after treatment. Conclusions: The obtained results indicate that ALA is effective in the treatment of second- and third-degree hemorrhoids. Larger, double-blind controlled trials are needed to confirm the results and to investigate optimal treatment regimens.
References
1 (2011) Lipoic acid – biological activity and therapeutic potential. Pharmacol. Rep. 63, 849–858.
2 (1995) Lipoic acid as a biological antioxidant. Free Radic. Biol. Med. 19, 227–250.
3 (2001) Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition. 17, 888–895.
4 (2015) Effects of α-lipoic acid and eicosapentaenoic acid in overweight and obese women during weight loss. Obesity. 23, 313–321.
5 (2013) Anti-obesity and lipid-lowering properties of alpha-lipoic acid. J. Hum. Nutr. Food Sci. 1, 1002.
6 (2009) Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential. Biochim. Biophys. Acta. 1790, 1149–1160.
7 (2013) Effects of combined lipoic acid and pyridoxine on albuminuria, advanced glycation end-products, and blood pressure in diabetic nephropathy. Int. J. Vitam. Nutr. Res. 83, 77–85.
8 (1996) NF-κB and IκB proteins: new discoveries and insights. Annu. Rev. Immunol. 14, 649–681.
9 (2008) Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer’s disease. Adv. Drug. Deliver. Rev. 60, 1463–1470.
10 (2007) Effect of combined treatment with α-lipoic acid and acetyl-L-carnitine on vascular function and blood pressure in patients with coronary artery disease. J. Clin. Hypertens. 9, 249–255.
11 (2005) Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome. Results of the irbesartan and lipoic acid in endothelial dysfunction (ISLAND) Study. Circulation. 111, 343–348.
12 (2008) Management of haemorrhoids. Br. Med. J. 16, 380–383.
13 (1994) Haemorrhoids: pathology, pathophysiology and aetiology. Br. J. Surg. 81, 946–954.
14 (2005) Bowel habits in hemorrhoid patients and normal subjects. Am. J. Gastroenterol. 100, 401–406.
15 (2014) Haemorrhoids: Overview. Emedicine.medscape.com. New York, USA: WebMD LLC.
16 (2012) Hemorrhoids: From basic pathophysiology to clinical management. World J. Gastroenterol. 18, 2009–2017.
17 (1994) Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo. Angiology. 45, 574–578.
18 (1994) Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids. Angiology. 45, 566–573.
19 (2000) Randomized clinical trial of micronized flavonoids in the early control of bleeding from acute internal haemorrhoids. Br. J. Surg. 87, 868–872.
20 (1974) Anthocyanosides as a new vasculotrophic agent in patients with hemorrhoids. Medicina (Mex). 54, 73–76.
21 (1992) A clinical trial of hydroxyethylrutosides in the treatment of haemorrhoids of pregnancy. J. Int. Med. Res. 20, 54–60.
22 (1992) Hydroxyethylrutosides. A review of its pharmacology, and therapeutic efficacy in venous insufficiency and related disorders. Drugs. 44, 1013–1032.
23 (2007) Analgesic, anti-inflammatory and venotonic effects of Cissus quadrangularis. J. Ethnopharmacol. 110, 264–270.
24 (2004) Clinical study of the Ginkgo biloba–troxerutin-heptaminol Hce in the treatment of acute hemorrhoidal attacks. J. Med. Ass. Thai. 87, 137–142.
25 (2001) Synergistic antioxidant compositions in management of hemorrhoids and other ano-rectal inflammatory conditions. US. 6242010, B1.
26 (2001) Integrated comprehensive hemorrhoid treatment compositions and regimen. Patent US 6228387 B1.
27 . (2012) WHO guidelines on nutrition. Geneva: WHO.
28 . (1996) Preparation and use of food-based dietary guidelines. Report of a joint FAO/WHO consultation Nicosia, Cyprus. WHO/NUT/96.6, Geneva, Switzerland.
29 . (1991) General principles for the addition of essential nutrients to foods. In International food standards. Rome, Italy: CAS.
30 (2007) Hemorrhoidal Disease: A comprehensive review. J. Am. Coll. Surg. Rev. 204, 102–117.
31 (2009) Wong’s essentials of pediatric nursing. (Ed. 8). St. Louis, MO, USA: Mosby.
32 (2010) Diagnosis and management of symptomatic hemorrhoids. Surg. Clin. North Am. 90, 17–32.
33 (1956) The latex fixation test. I.Application to the serologic diagnosis of rheumatoid arthritis. Am. J. Med. 21, 888–892.
34 (1988) Hematološke laboratorijske pretrage. Croatia: Sveučilišna naklada Liber Zagreb.
35 (2001) Hemorrhoids and varicose veins: a review of treatment options. Altern. Med. Rev. 6, 126–140.
36 (1960) Alpha-ketoglutaric dehydrogenase. 8. Isolation and some properties of a flavoprotein component. J. Biol. Chem. 235, 2485–2491.
37 (1994) Lipoic and dihydrolipoic acids as antioxidants. A critical evaluation. Free Rad. Res. 20, 119–133.
38 (1995) Thioctic (lipoic) acid: a therapeutic metal-chelating antioxidant? Biochem. Pharmacol. 50, 123–126.
39 (1996) Alpha-lipoic acid dependent regeneration of ascorbic acid from dehydroascorbic acid in rat liver mitochondria. J. Bioenerg. Biomembr. 28, 77–85.
40 (1988) Interplay between lipoic acid and glutathione in the protection against microsomal lipid peroxidation. Biochim. Biophys. Acta. 963, 558–561.
41 (1995) Lipoic acid as a biological antioxidant. Free Rad. Biol. Med. 19, 227–250.
42 (2015) Lipoic acid and N-acetylcysteine prevent ammonia-induced inflammatory response in C6 astroglial cells: The putative role of ERK and HO1 signaling pathways. Toxicol. In Vitro. 29, 1350–1357.
43 (2006) Lipoic acid inhibits expression of ICAM-1 and VCAM-1 by CNS endothelial cells and T cell migration into the spinal cord in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 175, 87–96.
44 (2013) Role of α-lipoic acid in dextran sulfate sodium-induced ulcerative colitis in mice: Studies on inflammation, oxidative stress, DNA damage and fibrosis. Food Chem. Toxicol. 59, 339–355.
45 (2013) Role of α-lipoic acid in dextran sulfate sodium-induced ulcerative colitis in mice: studies on inflammation, oxidative stress, DNA damage and fibrosis. Food Chem. Toxicol. 59, 339–55.
46 (2001) Beneficial effects of alphalipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Rad. Biol. Med. 31, 53–61.
47 (2003) Vascular endothelial dysfunction in aging: loss of Akt-dependent endothelial nitric oxide synthase phosphorylation and partial restoration by (R)-alpha-lipoic acid. Biochem. Soc. Trans. 31, 1447–1449.
48 (2001) Clinical study of pilex combination therapy vs conventional ayurvedic therapy in the management of haemorrhoids. Indian Pract. 11, 799–805.
49 (2004) Antioxidant herbal supplements for hemorrhoids – developing a new formula. NutraFoods. 3, 19–26.
50 (2013) The effect of lipoic acid and vitamin E therapies in individuals with the metabolic syndrome. Nutr. Metab. Cardiovasc. 23, 543–549.
51 (2012) Effects of alpha-lipoic acid supplementation on inflammation, oxidative stress and serum lipid profile levels in patients with end-stage renal disease on hemodialysis. J. Ren. Nutr. 22, 244–250.
